<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6460">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015976</url>
  </required_header>
  <id_info>
    <org_study_id>200803-272</org_study_id>
    <nct_id>NCT01015976</nct_id>
  </id_info>
  <brief_title>A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects</brief_title>
  <official_title>A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuropsychiatric Research Institute, Fargo, North Dakota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Dakota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuropsychiatric Research Institute, Fargo, North Dakota</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the difference, if any, in the area under the
      sertraline plasma level time curve (AUC) between patients who are nine to fifteen months
      post Roux-en-Y Bariatric Surgery and control subjects matched for body mass index (BMI), age
      and gender.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives include the determination of changes in mean CPmax, Time to CPmax and
      Volume of Distribution between the two groups. Also, assessment of subject tolerance of
      sertraline utilizing the UKU side effect rating scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>AUC Post Surgery (n =5) Compared to AUC Control (n=5)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC of surgery group compared to the AUC of control group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Post bariatric surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux en Y bariatric surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bariatric surgery</intervention_name>
    <description>Roux en Y bariatric surgery</description>
    <arm_group_label>Post bariatric surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>No surgery</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between the ages of 18 and 60 years.

          -  Subjects must be of good general health by history and physical exam.

          -  Five subjects 9 to 15 months past bariatric surgery (Roux-en-Y procedure), no BMI
             requirement.

          -  Five subjects matched for body mass index, age and sex to the post bariatric surgery
             group.

          -  No contraindications to receiving a single dose of 100 mg of sertraline.

          -  Women of child bearing potential must be practicing an accepted method of birth
             control (barrier method or oral contraception) and have a negative pregnancy test at
             baseline.

        Exclusion Criteria:

          -  Allergy to sertraline or any of its constituents.

          -  Candidates currently receiving sertraline or any other antidepressant.

          -  Candidates currently receiving a medication that interacts with sertraline (Zoloft)

          -  Candidates who are poor metabolizers for the CYP2D6 and/or 2C19 enzymes.

          -  Candidates experiencing clinically significant, unstable neurological, hepatic, renal
             or cardiovascular disease.

          -  Candidates currently or with a past history of meeting DSM-IV diagnostic criteria for
             schizophrenia, schizoaffective disorder, bipolar disorder.

          -  Candidates who have participated in an investigational drug study in past 30 days.

          -  Candidates who meet DSM-IV diagnostic criteria for drug/alcohol abuse or dependency
             or who have a history of drug/alcohol abuse or dependency.

          -  Candidates who are pregnant or nursing at time of study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Roerig, PharmD, BCPP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuropsychiatric Research Institute and University of North Dakota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuropsychiatric Research Institute</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nrifargo.com/</url>
    <description>Neuropsychiatric Research Institute</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>October 1, 2009</firstreceived_date>
  <firstreceived_results_date>October 28, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuropsychiatric Research Institute, Fargo, North Dakota</investigator_affiliation>
    <investigator_full_name>James Roerig</investigator_full_name>
    <investigator_title>James L. Roerig, Pharm.D., BCPP, University of North Dakota Department of Clinical Neuroscience, Grand Forks, ND and the Neuropsychiatric Research Institute, Fargo, ND.</investigator_title>
  </responsible_party>
  <keyword>Gastric Bypass</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Post surgery group Sertraline : Single dose of 100mg sertraline</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>active drug
No surgery matched subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Drug</title>
          <description>Single arm study, all receive active drug
Sertraline : Single dose of 100mg sertraline</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.6" spread="10.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC Post Surgery (n =5) Compared to AUC Control (n=5)</title>
        <description>AUC of surgery group compared to the AUC of control group</description>
        <time_frame>0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Single arm study, all receive active drug
Sertraline : Single dose of 100mg sertraline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC Post Surgery (n =5) Compared to AUC Control (n=5)</title>
            <description>AUC of surgery group compared to the AUC of control group</description>
            <units>ng-hr/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Post surgery</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124.4" spread="55.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Control</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="314.8" spread="129.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Drug</title>
          <description>Two arm study, all receive active drug
Sertraline : Single dose of 100mg sertraline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small sample size absence of men in either group. short data collection period, characterization of the linear elimination phase of the AUC was not possible.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James L. Roerig PharmD, BCPP</name_or_title>
      <organization>University of North Dakota - Neuropsychiatric Research Institute</organization>
      <phone>701 365 4919</phone>
      <email>jroerig@nrifargo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
